Literature DB >> 26943912

DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Aline Beckenkamp1,2, Samuel Davies1,2, Júlia Biz Willig2, Andréia Buffon3,4.   

Abstract

Dipeptidyl peptidase IV (DPPIV/CD26) is a multifunctional protein with intrinsic peptidase activity that inactivates or degrades some bioactive peptides. It is the main cellular binding protein for ecto-adenosine deaminase and interacts with extracellular matrix proteins, besides participating in different signaling pathways. Due to these multiple functions, DPPIV/CD26 has been shown to be closely related to the tumor process. It has been reported that the progression of certain types of cancer is accompanied by a decrease in DPPIV/CD26 expression, and studies have shown that the malignant phenotype can be reverted when DPPIV/CD26 expression is induced in these cancer cells, characterizing this protein as a tumor suppressor. On the other hand, DPPIV/CD26 was described as a protein associated with invasion and metastatic spread, characterizing it as a marker of malignancy. Thus, this review explores the roles of DPPIV/CD26 expression in tumor progression in different types of cancer and demonstrates the importance of this protein as a promising therapeutic target and tumor biomarker.

Entities:  

Keywords:  Biomarker; CD26; DPPIV; Marker of malignancy; Therapeutic target; Tumor suppressor

Mesh:

Substances:

Year:  2016        PMID: 26943912     DOI: 10.1007/s13277-016-5005-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  112 in total

1.  Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity.

Authors:  Petr Busek; Jarmila Stremenova; Lucie Sromova; Marek Hilser; Eva Balaziova; Dalibor Kosek; Jana Trylcova; Hynek Strnad; Evzen Krepela; Aleksi Sedo
Journal:  Int J Biochem Cell Biol       Date:  2012-01-28       Impact factor: 5.085

2.  Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.

Authors:  Thomas W Grunt; Alexandra Hebar; Sylvia Laffer; Renate Wagner; Barbara Peter; Harald Herrmann; Alexandra Graf; Martin Bilban; Martin Posch; Gregor Hoermann; Matthias Mayerhofer; Gregor Eisenwort; Christoph C Zielinski; Edgar Selzer; Peter Valent
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

3.  G1/S cell cycle arrest provoked in human T cells by antibody to CD26.

Authors:  Kei Ohnuma; Tomonori Ishii; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Masahiko Uchiyama; Hirotoshi Tanaka; Tadanori Yamochi; Nam H Dang; Chikao Morimoto
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

Review 4.  β1-integrin: a potential therapeutic target in the battle against cancer recurrence.

Authors:  Dalit Barkan; Ann F Chambers
Journal:  Clin Cancer Res       Date:  2011-09-07       Impact factor: 12.531

5.  Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha.

Authors:  P Proost; S Struyf; D Schols; C Durinx; A Wuyts; J P Lenaerts; E De Clercq; I De Meester; J Van Damme
Journal:  FEBS Lett       Date:  1998-07-31       Impact factor: 4.124

6.  Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands.

Authors:  M J Wilson; A R Ruhland; B J Quast; P K Reddy; S L Ewing; A A Sinha
Journal:  J Androl       Date:  2000 Mar-Apr

7.  Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.

Authors:  Ernest Y Tan; Michelle Mujoomdar; Jonathan Blay
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 8.  On the origin of serum CD26 and its altered concentration in cancer patients.

Authors:  Oscar J Cordero; Francisco J Salgado; Montserrat Nogueira
Journal:  Cancer Immunol Immunother       Date:  2009-06-26       Impact factor: 6.968

9.  CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion.

Authors:  P A Havre; M Abe; Y Urasaki; K Ohnuma; C Morimoto; N H Dang
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

10.  Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.

Authors:  Ivana Z Matić; Marija Ðorđić; Nađa Grozdanić; Ana Damjanović; Branka Kolundžija; Aleksandra Erić-Nikolić; Radan Džodić; Miomir Šašić; Srđan Nikolić; Danijela Dobrosavljević; Sanvila Rašković; Slađana Andrejević; Dušica Gavrilović; Oscar J Cordero; Zorica D Juranić
Journal:  BMC Immunol       Date:  2012-08-21       Impact factor: 3.615

View more
  17 in total

1.  A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers.

Authors:  Azka Ali; Alejandra Fuentes; William Paul Skelton; Yu Wang; Susan McGorray; Chintan Shah; Rohit Bishnoi; Long H Dang; Nam H Dang
Journal:  Mol Clin Oncol       Date:  2018-11-13

Review 2.  Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

Authors:  Petr Busek; Jonathan S Duke-Cohan; Aleksi Sedo
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

3.  Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.

Authors:  Joshua W Russo; Ce Gao; Swati S Bhasin; Olga S Voznesensky; Carla Calagua; Seiji Arai; Peter S Nelson; Bruce Montgomery; Elahe A Mostaghel; Eva Corey; Mary-Ellen Taplin; Huihui Ye; Manoj Bhasin; Steven P Balk
Journal:  Cancer Res       Date:  2018-09-21       Impact factor: 12.701

Review 4.  Proteases Revisited: Roles and Therapeutic Implications in Fibrosis.

Authors:  Jakub Kryczka; Joanna Boncela
Journal:  Mediators Inflamm       Date:  2017-05-31       Impact factor: 4.711

5.  Molecular Evidence of Adenosine Deaminase Linking Adenosine A2A Receptor and CD26 Proteins.

Authors:  Estefanía Moreno; Júlia Canet; Eduard Gracia; Carme Lluís; Josefa Mallol; Enric I Canela; Antoni Cortés; Vicent Casadó
Journal:  Front Pharmacol       Date:  2018-02-15       Impact factor: 5.810

6.  Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study.

Authors:  Rohit Bishnoi; Young-Rock Hong; Chintan Shah; Azka Ali; William P Skelton; Jinhai Huo; Nam H Dang; Long H Dang
Journal:  Cancer Med       Date:  2019-05-23       Impact factor: 4.452

7.  Suppressed Helicobacter pylori-associated gastric tumorigenesis in Fat-1 transgenic mice producing endogenous ω-3 polyunsaturated fatty acids.

Authors:  Young-Min Han; Kyung-Jo Kim; Migyeung Jeong; Jong-Min Park; Eun-Jin Go; Jing X Kang; Sung Pyo Hong; Ki Baik Hahm
Journal:  Oncotarget       Date:  2016-10-11

8.  Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer.

Authors:  Chintan Shah; Young-Rock Hong; Rohit Bishnoi; Azka Ali; William Paul Skelton; Long H Dang; Jinhai Huo; Nam H Dang
Journal:  Front Oncol       Date:  2020-03-31       Impact factor: 6.244

9.  Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer.

Authors:  Gustavo A Arias-Pinilla; Angus G Dalgleish; Satvinder Mudan; Izhar Bagwan; Anthony J Walker; Helmout Modjtahedi
Journal:  Sci Rep       Date:  2020-01-17       Impact factor: 4.379

10.  Hypoxia Regulates DPP4 Expression, Proteolytic Inactivation, and Shedding from Ovarian Cancer Cells.

Authors:  Laura R Moffitt; Maree Bilandzic; Amy L Wilson; Yiqian Chen; Mark D Gorrell; Martin K Oehler; Magdalena Plebanski; Andrew N Stephens
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.